discount semaglutide 🎉 New Year, New You! 🎉 We're excited to announce that our Weight Loss Program has been EXTENDED this January 2026! 🎯, Kickstart your wellness journey with our special on Semaglutide: enjoy Semaglutide coupon: How to save

Alcohol consumption while taking GLP-1 medications requires careful consideration

Emerging research, treatment potential, survival impact, and what it means for future cancer therapy.

Promotes weight loss by mimicking a GLP-1 hormone

Because the medication goes smoothly into the layer of fat just beneath the skin rather than a muscle layer, discomfort is exceptionally minimal, allowing patients to easily manage their weekly cycle at home with complete confidence

From oral formulations to agonist combinations, from muscle preservation to indication expansion, the question remains: who will be the next company to bring a GLP-1-based therapeutic to the market?The 2nd GLP-1-Based Therapeutics Summit is your dedicated platform for leaders and decision-makers to connect, collaborate, and continue to transform healthcare as we know it through the development of GLP-1s.URLs:Tickets: Developer Pricing* - Conference + 2 Workshops : USD 4197.00,Drug Developer Pricing* - Conference + 1 Workshop: USD 3598.00,Drug Developer Pricing* - Conference Only: USD 2999.00,Academic Pricing** - Conference + 2 Workshops: USD 3597.00,Academic Pricing** - Conference + 1 Workshop Only: USD 3098.00,Academic Pricing** - Conference Only: USD 2599.00,Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00,Solution Provider Pricing - Conference + 1 Workshop: USD 4398.00,Solution Provider Pricing - Conference Only: USD 3699.00Speakers: Adam Bell, Vice President, Translational Medicine and Regulatory Affairs, Neuraly, Andrew Young, Chief Scientific and Medical Officer, I2O Therapeutics, Belle van Rosmalen, Director - Incretin Outcomes, Eli Lilly and Co., Damian Bialonczyk, Global Medical Lead - Metabolism, Roche, David Glass, Vice President - Research, Regeneron, Elisa Araldi, Professor, University of Parma, Hong Chen, Director - Search and Evaluation, Novo Nordisk, Jason Mastaitis, Sr